48,453
edits
Difference between revisions of "Neuroendocrine tumour of the pancreas"
Jump to navigation
Jump to search
Neuroendocrine tumour of the pancreas (view source)
Revision as of 12:04, 14 March 2014
, 12:04, 14 March 2014→IHC
(→IHC) |
(→IHC) |
||
| Line 87: | Line 87: | ||
==IHC== | ==IHC== | ||
*CK19 +ve | *CK19 +ve. | ||
**Considered a poor prognostic factor<ref name=pmid19956064>{{Cite journal | last1 = Jain | first1 = R. | last2 = Fischer | first2 = S. | last3 = Serra | first3 = S. | last4 = Chetty | first4 = R. | title = The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. | journal = Appl Immunohistochem Mol Morphol | volume = 18 | issue = 1 | pages = 9-15 | month = Jan | year = 2010 | doi = 10.1097/PAI.0b013e3181ad36ea | PMID = 19956064 }}</ref> - disputed by an older paper.<ref>{{Cite journal | last1 = La Rosa | first1 = S. | last2 = Rigoli | first2 = E. | last3 = Uccella | first3 = S. | last4 = Novario | first4 = R. | last5 = Capella | first5 = C. | title = Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours. | journal = Histopathology | volume = 50 | issue = 5 | pages = 597-606 | month = Apr | year = 2007 | doi = 10.1111/j.1365-2559.2007.02662.x | PMID = 17394496 }}</ref> | |||
*Chromogranin +ve. | *Chromogranin +ve. | ||
*Synaptophysin +ve. | *Synaptophysin +ve. | ||